Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An in vitro chemoresponse assay defines a subset of colorectal and lung carcinomas responsive to cetuximab.

Cancer biology & therapy - 15 Jan 2011

Rice Shara D, Cassino Theresa R, Sakhamuri Lahari, Song Nan, Williams Karl E, Brower Stacey L

Abstract excerpt

Cetuximab is a chimeric monoclonal antibody for the epidermal growth factor receptor (EGFR) that may provide benefit to select cancer patients; however, identification of the characteristics of those patients who may benefit from its use is not complete. The ChemoFx® drug response marker (DRM) is an in vitro assay that can provide drug response data on tumor specimens before any patient treatment is initiated. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal

Share to Biological Assay

Share to Cell Line, Transformed

Share to Drug Screening Assays, Antitumor

Share to Feasibility Studies

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 20980824
DOI: 10.4161/cbt.11.2.13701

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

An in vitro chemoresponse assay defines a subset of colorectal and lung carcinomas responsive to cetuximab.PMID 20980824Read ↗

In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer.Semantic proximity Read ↗

EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.Semantic proximity Read ↗

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.Semantic proximity Read ↗

EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.Semantic proximity Read ↗

Histoculture drug response assay for gefitinib in non-small-cell lung cancer.Semantic proximity Read ↗

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).Semantic proximity Read ↗

Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation.Semantic proximity Read ↗

Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer.Semantic proximity Read ↗

Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.